eligibility_summary
Eligible patients: prescribed ofatumumab within UK marketing authorization at participating MS clinics (with/without KC PSP) during the index window, with authorized data access (alive with consent or deceased with provider access). Adherence analyses require ≥6 months post-index follow-up, effectiveness requires ≥6 months pre-index and ≥6 months post-index. Exclusion: any off-label ofatumumab use.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial type: Retrospective, non-interventional study of patients with relapsing-remitting MS treated with ofatumumab, assessing adherence and clinical outcomes, cohorts compared clinics using vs not using the Kesimpta Connect patient support program. Drug/intervention: Ofatumumab (Kesimpta) — fully human IgG1 monoclonal antibody, anti-CD20 B‑cell depleting therapy given by subcutaneous injection. Mechanism of action: Binds CD20 on B lymphocytes and induces depletion via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity/phagocytosis, and apoptosis. Target cells/pathways: CD20+ pre‑B to mature B cells, reduces B‑cell antigen presentation, cytokine production, and B–T cell co-stimulation, lowering inflammatory activity in MS, spares stem cells and plasma cells. No other drugs tested.